Focused and Intracellular Antibacterial Exercise in opposition to S. agalactiae of the Chimeric Peptides Based mostly on Pheromone and Cell-penetrating Peptides
The importance of the complicated bacterial ecosystem within the human physique and the obstacle of the mammalian membrane in opposition to many antibiotics collectively emphasize the need to develop antimicrobial brokers with exact antimicrobial and cell-penetrating actions. A easy and possible technique for producing dual-function antimicrobial peptides impressed by extremely hydrophobic peptide pheromone and cationic cell-penetrating peptides is introduced.
Moreover, the extension of peptides candidate library is achieved by modifying the charged area. The bacteria-selective peptides L1, L2, L10 and L11 kill S. agalactiae by disrupting the membrane construction and the focused mechanism is recommended that the peptides offset the entrapment of S. agalactiae reasonably than of others micro organism.
Furthermore, L2 and L10 possess intracellular antibacterial exercise and provider property, which is especially depending on endocytosis. Given their appropriate biocompatibility, excessive tolerance, no drug resistance and efficient antimicrobial capability in a mouse mastitis mannequin, L2 and L10 will be highly effective weapons in opposition to S. agalactiae pathogen an infection.
PSTAIR Peptide |
|||
070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Lv (Rat) |
|||
008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
NGR Peptide 1 |
|||
025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Anorexigenic Peptide |
|||
070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
Peptide B (Bovine) |
|||
024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
ExE peptide M3mP6 |
|||
064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
PLP Peptide (103-116) (Bovine) |
|||
070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
Heparin Binding Peptide |
|||
025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
PGMtide Control Peptide |
|||
040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Obesity Peptide Library |
|||
L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - Cy3 Labeled |
|||
FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
FGL Peptide - FAM Labeled |
|||
FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Pedal Peptide (Pep) (Aplysia) |
|||
047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
FGL Peptide - FITC Labeled |
|||
FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
AF-16 Peptide - Antibody |
|||
H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
Schizophrenia Related Peptide |
|||
047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Insulin B (22-25) Peptide |
|||
035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
Eosinophilotactic Peptide (AGSE) |
|||
070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Cell Penetrating ARF Peptide (26-44) |
|||
068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
FGL Peptide - Biotin Labeled |
|||
B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Gastrointestinal Peptide Library |
|||
L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
Peptide R / CXCR4 Antagonist |
|||
030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - Cy3 Labeled |
|||
FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Peptide - FAM Labeled |
|||
FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
[D-Ala1]-Peptide T amide |
|||
057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Catch-Relaxing Peptide (CARP) |
|||
047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
Calmodulin Binding Peptide 1 |
|||
070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
FGL Peptide - Rhodamine Labeled |
|||
FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Glycogenolysis-Inhibiting Peptide |
|||
023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Anti-Inflammatory Peptide 1 |
|||
004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Urokinase-Derived Peptide A6 |
|||
025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Peptide 34 / GPR-54 Agonist |
|||
048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide-Depleted Plasma (Human) |
|||
MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Antimicrobial Trp-rich peptide |
|||
004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Myosin Kinase Inhibiting Peptide |
|||
058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Peptide YY (PYY) (3-36) (Human) |
|||
059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
PGMtide Peptide - Rhodamine Labeled |
|||
FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
Peptide YY (PYY) (Human) - Antibody |
|||
H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Peptide A / p60v-src (137-157) |
|||
058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
pro-Opionmelanocortin / J Peptide |
|||
022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Cancer-Targeting Peptide Library |
|||
L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
C28 optimized peptide 6 (Human) |
|||
073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
Kemptide / Phosphate Acceptor Peptide |
|||
058-16 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Self-Meeting M2e-Based mostly Peptide Nanovaccine Confers Broad Safety In opposition to Influenza Viruses
The extracellular area of influenza M2 protein (M2e) is extremely conserved and is a promising goal for improvement of common influenza vaccines. Right here, we synthesized a peptide vaccine consisting of M2e epitope linked to a fibrillizing peptide, which might self-assemble into nanoparticle in physiological salt options.
When administrated into mice with out further adjuvant, the influenza A M2e epitope-bearing nanoparticles induced antibodies in opposition to M2e of various influenza subtypes. Evaluating with different M2e-based vaccine, these M2e nanoparticles didn’t induce immune response in opposition to the fibrillizing peptide, demonstrating minimal immunogenicity of vaccine provider.
Moreover, vaccination with M2e-based nanoparticles didn’t solely defend mice in opposition to homologous problem of influenza PR8 H1N1 virus, but in addition present safety in opposition to heterologous problem of extremely pathogenic avian influenza H7N9 virus. These outcomes indicated that M2e-based self-assembled nanoparticle vaccine is protected and may elicit cross-protection, due to this fact is a promising candidate of common influenza vaccines.
Antimicrobial resistance of ocular microbes and the function of antimicrobial peptides
Isolation of antimicrobial-resistant microbes from ocular infections could also be changing into extra frequent. Infections brought on by these microbes will be troublesome to deal with and result in poor outcomes. Nevertheless, new therapies are being developed which can assist enhance scientific outcomes. This evaluation examines latest experiences on the isolation of antibiotic-resistant microbes from ocular infections. As well as, an summary of the event of some new antibiotic therapies is given.
The latest literature relating to antibiotic use and resistance, isolation of antibiotic-resistant microbes from ocular infections and the event of potential new antibiotics that can be utilized to deal with these infections was reviewed. Ocular microbial infections are a world public well being subject as they may end up in imaginative and prescient loss which compromises high quality of life.
Roughly 70 per cent of ocular infections are brought on by micro organism together with Chlamydia trachomatis, Staphylococcus aureus, and Pseudomonas aeruginosa and fungi comparable to Candida albicans, Aspergillus spp. and Fusarium spp.
Resistance to first-line antibiotics comparable to fluoroquinolones and azoles has elevated, with resistance of S. aureus isolates from the USA to fluoroquinolones reaching 32 per cent of isolates and 35 per cent being methicillin-resistant (MRSA).
Decrease ranges of MRSA (seven per cent) had been remoted by an Australian research. Antimicrobial peptides, that are broad-spectrum alternate options to antibiotics, have been examined as doable new medication. A number of have proven promise in animal fashions of keratitis, particularly treating P. aeruginosa, S. aureus or C. albicans infections.
Reviews of accelerating resistance of ocular isolates to mainstay antibiotics are a priority, and there may be proof that for ocular floor illness this resistance interprets into worse scientific outcomes.
New antibiotics are being developed, however not by massive pharmaceutical firms and principally in college analysis laboratories and smaller biotech firms. Antimicrobial peptides present promise in treating keratitis.
Alleviation of Despair by Glucagon-Like Peptide 1 By the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Perform
Despair has emerged as a significant reason behind mortality globally. Many research have reported danger elements and mechanisms related to despair, however it’s as but unclear how these findings will be utilized to the remedy and prevention of this dysfunction.
The onset and recurrence of despair have been linked to numerous metabolic elements, together with hyperglycemia, dyslipidemia, and insulin resistance. Latest research have urged that despair is accompanied by reminiscence loss in addition to depressive temper. Thus, many researchers have highlighted the connection between depressive conduct and metabolic alterations from numerous views.
Glucagon-like peptide-1 (GLP-1), which is secreted from intestine cells and hindbrain areas, has been studied in metabolic ailments comparable to weight problems and diabetes, and was proven to regulate glucose metabolism and insulin resistance. Not too long ago, GLP-1 was highlighted as a regulator of numerous pathways, however its potential because the therapeutic goal of depressive dysfunction was not described comprehensively. Due to this fact, on this evaluation, we centered on the potential of GLP-1 modulation in despair.
Adjuvant Peptide |
|||
070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Lv (Rat) |
|||
008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
NGR Peptide 1 |
|||
025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Anorexigenic Peptide |
|||
070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
Peptide B (Bovine) |
|||
024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
ExE peptide M3mP6 |
|||
064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
PLP Peptide (103-116) (Bovine) |
|||
070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
Heparin Binding Peptide |
|||
025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
PGMtide Control Peptide |
|||
040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Obesity Peptide Library |
|||
L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - Cy3 Labeled |
|||
FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
FGL Peptide - FAM Labeled |
|||
FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Pedal Peptide (Pep) (Aplysia) |
|||
047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
FGL Peptide - FITC Labeled |
|||
FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
AF-16 Peptide - Antibody |
|||
H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
Schizophrenia Related Peptide |
|||
047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Insulin B (22-25) Peptide |
|||
035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
Eosinophilotactic Peptide (AGSE) |
|||
070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Cell Penetrating ARF Peptide (26-44) |
|||
068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
FGL Peptide - Biotin Labeled |
|||
B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Gastrointestinal Peptide Library |
|||
L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
Peptide R / CXCR4 Antagonist |
|||
030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - Cy3 Labeled |
|||
FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Peptide - FAM Labeled |
|||
FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
[D-Ala1]-Peptide T amide |
|||
057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Catch-Relaxing Peptide (CARP) |
|||
047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
Calmodulin Binding Peptide 1 |
|||
070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
FGL Peptide - Rhodamine Labeled |
|||
FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Glycogenolysis-Inhibiting Peptide |
|||
023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Anti-Inflammatory Peptide 1 |
|||
004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Urokinase-Derived Peptide A6 |
|||
025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Peptide 34 / GPR-54 Agonist |
|||
048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide-Depleted Plasma (Human) |
|||
MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Antimicrobial Trp-rich peptide |
|||
004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Myosin Kinase Inhibiting Peptide |
|||
058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Peptide YY (PYY) (3-36) (Human) |
|||
059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
PGMtide Peptide - Rhodamine Labeled |
|||
FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
Peptide YY (PYY) (Human) - Antibody |
|||
H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Peptide A / p60v-src (137-157) |
|||
058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
pro-Opionmelanocortin / J Peptide |
|||
022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Cancer-Targeting Peptide Library |
|||
L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
C28 optimized peptide 6 (Human) |
|||
073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
Kemptide / Phosphate Acceptor Peptide |
|||
058-16 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Bioactive Secretory Peptide Library |
|||
L-009 | PHOENIX PEPTIDE | 1016 peptides | EUR 31350.24 |
Peptide YY (PYY) (Human) - EIA Kit |
|||
EK-059-01 | PHOENIX PEPTIDE | 96 wells | EUR 617.76 |
Peptide YY (PYY) (Human) - RIA Kit |
|||
RK-059-01 | PHOENIX PEPTIDE | 125 tubes | EUR 814.32 |
Galanin-Like Peptide (GALP) (Rat) |
|||
026-52 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
PACAP-Related Peptide (PRP) (Rat) |
|||
052-11 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
T-064-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Crustacean Cardioactive Peptide (CCAP) |
|||
047-24 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Virus Replication Inhibiting Peptide |
|||
070-85 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
Pri Peptide from sORF pri RNA |
|||
069-77 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Alzheimer Fingerprint Peptide Library |
|||
L-011 | PHOENIX PEPTIDE | 85 peptides | EUR 6529.68 |
Annexin A1 Binding Peptide, IF7CRR |
|||
025-72 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Galanin-Like Peptide (GALP) (Human) |
|||
026-51 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Rat) |
|||
027-32 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
FMRF-Like Peptide (Helix aspersa) |
|||
047-31 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
PACAP-Related Peptide (PRP) (Human) |
|||
052-10 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Scrambled Control for Pri Peptide |
|||
069-78 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
u PAR (84-95) Scrambled Peptide |
|||
072-47 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Kinetensin / Neurotensin Related Peptide |
|||
048-01 | PHOENIX PEPTIDE | 500 μg | EUR 58.32 |
Gastrin Releasing Peptide (GRP) (Frog) |
|||
027-33 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
Small Cardioactive Peptide A (SCPA) |
|||
047-76 | PHOENIX PEPTIDE | 1 mg | EUR 64.8 |
Epidermal Growth Factor Receptor Peptide (985-996) |
|||
030-05 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|||
G-064-07 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Galanin-Like Peptide (GALP) (Porcine) |
|||
026-50 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Human) |
|||
027-07 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Gastrin Releasing Peptide (GRP) (Mouse) |
|||
027-40 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
PGMtide Control Peptide - Cy3 Labeled |
|||
FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Control Peptide - FAM Labeled |
|||
FG-040-70A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
Growth Blocking Peptide - FAM Labeled |
|||
FG-046-92A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Chop-Suey / Variety Peptide Library |
|||
L-001 | PHOENIX PEPTIDE | 238 peptides | EUR 7400.16 |
T3 Peptide / Tumstatin (69-88) (Human) |
|||
016-50 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
T7 Peptide / Tumstatin (74-98) (Human) |
|||
016-51 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Peptide YY (PYY) (1-36)-Gly (Human) |
|||
059-07 | PHOENIX PEPTIDE | 100 μg | EUR 295.92 |
Peptide YY (PYY) (3-36)-Gly (Human) |
|||
059-08 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide YY (PYY) (2-36)-Gly (Human) |
|||
059-11 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Peptide YY (PYY) (4-36)-Gly (Human) |
|||
059-12 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Hypocholesterolemic Peptide / IIAEK (Bovine) |
|||
028-37 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Fractalkine Chemokine Domain peptide (41-52) (Human) |
|||
026-82 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Fractalkine Chemokine Domain peptide (53-60) (Human) |
|||
026-83 | PHOENIX PEPTIDE | 200 μg | EUR 135 |
Fractalkine Chemokine Domain peptide (60-71) (Human) |
|||
026-84 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
FMRF-Like Peptide ( Lymnae stagnalis) |
|||
047-30 | PHOENIX PEPTIDE | 5 mg | EUR 129.6 |
Peptide F (Bovine) - I-125 Labeled |
|||
T-024-58 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Kappa-Receptor, C-terminal peptide |
|||
002-98 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Angiotensin II - constrained peptide 1 |
|||
004-09 | PHOENIX PEPTIDE | 500 μg | EUR 165.24 |
VEGFR binding peptide KH / QKRKRKKSRKKH |
|||
007-58 | PHOENIX PEPTIDE | 100 μg | EUR 158.76 |
Stresscopin Related Peptide (SRP) (Human) |
|||
019-27 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Gastrin Releasing Peptide (GRP) (Porcine) |
|||
027-13 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Delta-Sleep-Inducing Peptide (DSIP) |
|||
070-22 | PHOENIX PEPTIDE | 500 μg | EUR 27 |
[Thr5]-Speract / Sperm Activating Peptide |
|||
070-71 | PHOENIX PEPTIDE | 1 mg | EUR 114.48 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled Purified IgG |
|||
T-G-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
[D-Ala1]-Peptide T - Biotin Labeled |
|||
B-057-02 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
F3 Peptide (4-13) / HMGN2 Fragment 3 (4-13) |
|||
004-13 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
PGMtide Control Peptide - Biotin Labeled |
|||
B-040-70 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Growth Blocking Peptide - Biotin Labeled |
|||
B-046-92 | PHOENIX PEPTIDE | 20 μg | EUR 336.96 |
Orphan Receptor Peptide Ligand Library |
|||
L-005 | PHOENIX PEPTIDE | 150 peptides | EUR 7938 |
Nesfatin-1-Like Peptide (NLP) (Rat) |
|||
009-85 | PHOENIX PEPTIDE | 100 μg | EUR 461.16 |
SHAAG Peptide / Chemokine (46-63) (Human) |
|||
072-32 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
C28 optimized peptide 15 Dimer (Human) |
|||
073-86 | PHOENIX PEPTIDE | 100 μg | EUR 420.12 |
Prolactin-Releasing Peptide-31 (PrRP-31) (Rat) |
|||
008-52 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
Prolactin-Releasing Peptide-20 (PrRP-20) (Rat) |
|||
008-53 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
Osteoblast Activating Peptide (OBAP) (Human) |
|||
055-52 | PHOENIX PEPTIDE | 100 μg | EUR 199.8 |
Human Proteome Signature Peptide Library |
|||
L-010 | PHOENIX PEPTIDE | 98 peptides | EUR 7804.08 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled Purified IgG |
|||
T-G-064-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |